Publications by authors named "D Duboc"
Background Chronic respiratory failure and heart involvement may occur in Duchenne muscular dystrophy. We aimed to assess the prognostic value of the right ventricular (RV) systolic dysfunction in patients with Duchenne muscular dystrophy. Methods and Results We studied 90 genetically proven patients with Duchenne muscular dystrophy from 2010 to 2019, to obtain respiratory function and Doppler echocardiographic RV systolic function.
View Article and Find Full Text PDFArticle Synopsis
- Patients with mitochondrial diseases are at a higher risk for heart failure (HF) and serious heart-related events, prompting the creation of prediction models to estimate these risks.
- In a study involving 600 adult patients, over 6.67 years, 4.9% developed HF, and 5.1% experienced arrhythmic major adverse cardiac events (MACE).
- Key predictors for these heart issues included specific genetic variants, heart structure changes, and reduced heart function as indicated by low ejection fractions.*
Article Synopsis
- This document serves as a comprehensive guide for health care professionals on managing arrhythmias associated with neuromuscular disorders (NMDs), focusing on various specific conditions like Duchenne muscular dystrophy and myotonic dystrophy.
- It includes expert-recommended practices for diagnosing and treating arrhythmic complications, as well as provides insights into end-of-life care for these patients.
- The recommendations are based on extensive research, a consensus from specialists, and have undergone public and professional review to ensure effective and reliable clinical guidance.
Synthetized by the liver and metabolized by the gut microbiota, BA are involved in metabolic liver diseases that are associated with cardiovascular disorders. Animal models of atheroma documented a powerful anti-atherosclerotic effect of bile acids (BA). This prospective study examined whether variations in circulating BA are predictive of coronary artery disease (CAD) in human.
View Article and Find Full Text PDFArticle Synopsis
- The American College of Cardiology/American Heart Association suggests ACE inhibitors (ACE-i) for patients with non-ischemic cardiomyopathy when their left ventricular ejection fraction (LVEF) drops below 40%.
- This study investigates whether starting ACE-i treatment earlier, at an LVEF below 50%, leads to better long-term heart health outcomes in patients with Becker muscular dystrophy cardiomyopathy compared to the standard practice.
- Results show that patients receiving early ACE-i treatment had significantly lower rates of hospitalization for heart failure and less severe decreases in LVEF, indicating improved cardiac outcomes compared to those starting treatment with LVEF below 40%.